We have cheap energy, you chose well, said Babiš. Novo Nordisk invested eight billion near Prague in a 'weight-loss factory'

▤ Summary

Novo Nordisk has officially started production at its site near Prague, turning a former Covid vaccine ingredient plant into a facility for diabetes and obesity medicines. The company invested eight billion Czech crowns in the site. The move expands its manufacturing footprint in Central Europe and ties the local plant to one of the fastest-growing areas in pharma. The article highlights the shift from vaccine-related production to a new long-term role in weight-loss and diabetes drug supply.

▦ Linked Companies